EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Role of [18F]FDG PET/CT Prior to and During Neoadjuvant Chemotherapy for Soft Tissue Sarcomas

Stijn J C van der Burg, Bernies van der Hiel iD, Lotte Heimans, J Martijn Kerst iD, Michel W J M Wouters iD, Petur Snaebjornsson iD, Yvonne M Schrage iD, Winette T A van der Graaf iD, Winan J van Houdt iD

Current Oncology · 2025

DOI: 10.3390/curroncol32050257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Stijn J C van der Burg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital (NKI-AVL), Plesmanlaan 121, 1066 CX Amsterdam, The Net…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Sarcoma, Neoadjuvant Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This retrospective, single-center study investigates the association between PET parameters and pathological response or disease recurrence in patients with soft tissue sarcoma (STS) treated with neoadjuvant chemotherapy (NACT). The maximum standardized uptake value (SUVmaxBL), metabolic tumor volume (MTVBL), and total lesion glycolysis (TLGBL) were measured at baseline [18F]FDG PET/CT and the change in percentage (ΔSUVmax, ΔMTV, ΔTLG) from baseline to early evaluation [18F]FDG PET/CT was calculated. The optimal cutoff values of the different PET parameters for pathological response, defined as 15% fibrosis/hyalinization, and recurrence-free survival were obtained for analysis. Forty-two patients who underwent baseline [18F]FDG PET/CT and NACT followed by surgery were included between January 2015 and January 2023. The primary diagnoses were angiosarcoma (n = 15), leiomyosarcoma (n = 15), sarcoma not otherwise specified (n = 9) and synovial sarcoma (n = 3). Twenty-eight (66.6%) patients underwent an early evaluation PET/CT. MTVBL, TLGBL, and ΔSUVmax (p = 0.024; p = 0.042, p = 0.009, respectively) values above the cutoff were associated with a pathological response based on RVT. ΔSUVmax, ΔMTV, and ΔTLG (p = 0.002; p = 0.019; p = 0.039, respectively) values above the cutoff were positively related to >15% fibrosis/hyalinization. MTVBL, TLGBL, and ΔMTV (p = 0.014; p = 0.022; p = 0.034, respectively) values above the cutoff were prognostic for the recurrence of disease. [18F]FDG PET/CT has a promising role in STS patients treated with NACT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18SarcomaNeoadjuvant TherapyHumansFemaleMaleMiddle AgedRetrospective StudiesAdultAged

Stichwörter der Autor:innen

[18F]FDG PET/CTdisease recurrenceneoadjuvant chemotherapypathologic responsesoft tissue sarcoma

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital (NKI-AVL), Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Department of Nuclear Medicine, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital (NKI-AVL), Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital (NKI-AVL), Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Department of Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital (NKI-AVL), Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.

ORCID-Profile: Bernies van der Hiel, J Martijn Kerst, Michel W J M Wouters, Petur Snaebjornsson, Yvonne M Schrage, Winette T A van der Graaf, Winan J van Houdt

Zitieren

APA

van der Burg, S. J. C., van der Hiel, B., Heimans, L., Kerst, J. M., Wouters, M. W. J. M., Snaebjornsson, P., Schrage, Y. M., van der Graaf, W. T. A., & van Houdt, W. J. (2025). The Role of [18F]FDG PET/CT Prior to and During Neoadjuvant Chemotherapy for Soft Tissue Sarcomas. Current Oncology. https://doi.org/10.3390/curroncol32050257

Vancouver

van der Burg SJC, van der Hiel B, Heimans L, Kerst JM, Wouters MWJM, Snaebjornsson P, et al. The Role of [18F]FDG PET/CT Prior to and During Neoadjuvant Chemotherapy for Soft Tissue Sarcomas. Current Oncology. 2025. doi:10.3390/curroncol32050257

BibTeX
@article{vanderBurg2025,
  author = {van der Burg, Stijn J C and van der Hiel, Bernies and Heimans, Lotte and Kerst, J Martijn and Wouters, Michel W J M and Snaebjornsson, Petur and Schrage, Yvonne M and van der Graaf, Winette T A and van Houdt, Winan J},
  title = {The Role of [18F]FDG PET/CT Prior to and During Neoadjuvant Chemotherapy for Soft Tissue Sarcomas},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32050257}
}
Kostenlos starten →